-
Adial Pharmaceuticals ( NASDAQ: ADIL ) appoints Cary J. Claiborne as President and CEO.
-
Mr. Claiborne takes over the role of William Stilley, who was appointed to the newly created position of CEO of Purnovate.
-
Both executives will remain on the Board of Directors of Adial. The Company also announced that Kevin Schuyler, who has served as Vice Chairman and as an independent director, has been appointed Chairman.
- Mr. Claiborne was appointed Chief Operating Officer of Adial in December 2022 after previously being named to the Board of Directors. Mr. Claiborne brings extensive experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies.
For further details see:
Adial Pharmaceuticals names new executive chief